Adults aged ≥75 years are recommended to receive RSV vaccine

A single dose of RSV vaccine is recommended for all adults aged ≥75 years. RSV hospitalisation rates increase with age, and people aged ≥75 years are likely to have the greatest benefit from vaccination.

RSV vaccine may be given at any time of the year but, where possible, should be offered before the start of the RSV season, which typically occurs from April to September. Adults recommended to receive an RSV vaccine, who have previously had an RSV infection, can receive it once they are recovered.

Either Abrysvo or Arexvy may be used, with no brand preference.

Protection lasts for at least 2 years. Recommendations on revaccination will be updated when data become available.

Arexvy is funded under the National Immunisation Program (NIP) for all adults aged ≥75 years.